Company file · RMD
ResMed
ResMed's revenue rose 9.9% in FY2026, to $5.7B, and net income rose 8.8% to $1.5B
Revenue rose 9.9% to $5.7B in FY2026, from $5.1B in FY2025. Net income rose 8.8% to $1.5B. Sleep and Breathing Health was the largest segment, at 88% of revenue.
Key facts
ResMed (NYSE: RMD) closed fiscal 2026 on Jun 30, 2026 with revenue of $5.7B, up 9.9% from a year before; net income came to $1.5B, up 8.8%. Its newest quarterly report covers the three months to Sep 30, 2026: revenue of $1.4B, up 5.9% on the same stretch of the prior year, and net income of $418M. Broken down by segment, Sleep and Breathing Health led with 88% of fiscal 2026 revenue. Sources: 10-K for fiscal 2026 (filed Aug 13, 2026) and 10-Q for the quarter ended Sep 30, 2026 (filed Oct 30, 2026).
Source: 10-K FY2026, filed Aug 13, 2026
Source: 10-Q filed Oct 30, 2026
How it makes money
By segment, FY2026
- LineAmountSharevs FY2025
- Sleep and Breathing Health$5.0B88%+10.5%
- Residential Care Software$676M12%+5.4%
Source: 10-K FY2026, XBRL breakdown
By segment in FY2026: Sleep and Breathing Health (88%) and Residential Care Software (12%), as shares of total revenue. Total revenue was $5.7B.
Source: 10-K FY2026
By product or service, FY2026
Share is of the FY2026 total; the last column is the change from FY2025.
Learn more: Revenue vs. net income · Gross, operating and net margin
What changed last quarter
Comparing Q1 FY2027 (Jul to Sep 2026) compared with Q1 FY2026 (Jul to Sep 2025)
Each pair of bars shows the dollar amount for both quarters. Longer bar, more money. Bars in a group share one scale.
Q1 FY2027Q1 FY2026
Company
Source: ResMed 10-Q for the quarter ended Sep 30, 2026, filed Oct 30, 2026
By segment
Source: ResMed 10-Q for the quarter ended Sep 30, 2026, filed Oct 30, 2026
The bull case and the bear case
The bull case
- Revenue rose 9.9% in FY2026 to $5.7B, from $5.1B a year earlier. 10-K, FY2026
- Net income rose 8.8% in FY2026 to $1.5B, from $1.4B. 10-K, FY2026
- Operating cash flow rose 3.1% in FY2026 to $1.8B. 10-K, FY2026
- Revenue in the quarter ended Sep 30, 2026 was $1.4B, up 5.9% on a year earlier. 10-Q, quarter ended Sep 30, 2026
The bear case
- The company's own risk factors are in Item 1A of its 10-K. Risks common in this industry include regulation; pricing and reimbursement; competition. 10-K, Item 1A
What optimists and skeptics tend to point to, each tied to a filing. Ticker Sage doesn't pick a side, and neither list is a reason to buy or sell.
What the company does
ResMed is in the health care equipment industry, part of the health care sector. The SEC files it under Surgical & Medical Instruments & Apparatus.
ResMed reports 2 segments: Sleep and Breathing Health and Residential Care Software.
Its fiscal year ends in June; the latest, FY2026, ended Jun 30, 2026.
Source: 10-K, Item 1 Business
Risks common in this industry
These are general risks for companies in the health care equipment industry. They are not a summary of ResMed’s own risk factors; for those, read Item 1A of its latest 10-K, linked below.
- RegulationApprovals, safety rules and government oversight shape what it can sell and how.
- Pricing and reimbursementPayers, insurers and governments influence what it can charge.
- CompetitionNew treatments, generics and rival products can take share.
- LitigationProduct liability and other legal claims can lead to costs.
- SupplyManufacturing and supplier problems can interrupt products.
Source: 10-K, Item 1A Risk Factors (the company's own list, in the company's words)
Three years of key numbers
Every number links to its filing; hover for the XBRL tag. A dash means the number isn't cleanly available, and we don't estimate it.
| US$ | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Revenue | $4.7B | $5.1B | $5.7B |
| Net income | $1.0B | $1.4B | $1.5B |
| Operating cash flow | $1.4B | $1.8B | $1.8B |
| Cash & equivalents (year end) | $238M | $1.2B | $1.5B |
| Total debt (year end) | $707M | $668M | $659M |
| Diluted shares | 148M | 147M | 146M |
- Revenue: Total revenue for the fiscal year, as the company reports it on its income statement.
- Net income: Net income attributable to the company's shareholders, after all costs, interest and taxes.
- Operating cash flow: Cash the business brought in from its day-to-day operations during the year (cash flow statement).
- Cash & equivalents: Cash and short-term investments that count as cash equivalents on the balance sheet. Excludes longer-dated marketable securities.
- Total debt: Short-term borrowings plus long-term debt, at carrying value.
- Diluted shares: Weighted average shares outstanding for the year, including the effect of options and stock awards.
Learn more: How to read an income statement · Earnings per share, basic and diluted · Free cash flow · How to read a balance sheet · Growth rate calculator · P/E calculator · Market cap calculator · Free cash flow calculator · Return on equity and assets calculator
Explainers for this page
- Segment reporting
- Net debt and net cash
- Debt-to-equity ratio
- Risk factors (Item 1A)
- The cash flow statement
- Margin accounts
- Treasury stock
Plain-English guides to terms this file uses, with real numbers from filings.
About these numbers
- ResMed names its fiscal year by the calendar year in which it ends, so FY2026 is the year that ended Jun 30, 2026.
Recent filings
| Form | Filed | Period |
|---|---|---|
| 10-Q | Oct 30, 2026 | Sep 30, 2026 |
| DEF 14A | Oct 1, 2026 | Jun 30, 2026 |
| 10-K | Aug 13, 2026 | Jun 30, 2026 |
Learn more: 10-K vs. 10-Q vs. 8-K · Form 4 insider filings · Fiscal years and quarters
Common questions about ResMed
How does ResMed make money?
Fiscal 2026 revenue: $5.7B. By segment in FY2026: Sleep and Breathing Health (88%) and Residential Care Software (12%), as shares of total revenue. Total revenue was $5.7B. Source: 10-K for fiscal 2026, filed Aug 13, 2026.
What was ResMed's revenue in fiscal 2026?
$5.7B, up 9.9% from fiscal 2025 ($5.1B). The year ended Jun 30, 2026; for fiscal 2024 the figure was $4.7B. Source: 10-K for fiscal 2026, filed Aug 13, 2026.
Is ResMed profitable?
Net income was $1.5B in fiscal 2026 (up 8.8%; fiscal 2025 was $1.4B). That counts as a GAAP profit. The latest quarter, ended Sep 30, 2026: net income was $418M. The page's About these numbers section explains what is included. Source: 10-K for fiscal 2026, filed Aug 13, 2026.
What did ResMed report in its latest quarterly filing?
For the three months to Sep 30, 2026: revenue $1.4B (up 5.9% from $1.3B) and net income $418M (up 20.0% from $349M). Source: 10-Q for the quarter ended Sep 30, 2026, filed Oct 30, 2026.
How much cash and debt does ResMed have?
As of Sep 30, 2026: $1.0B of cash and cash equivalents, $410M of total debt. Total debt here is short-term borrowings plus long-term debt, at carrying value. Source: 10-Q filed Oct 30, 2026.
What are the main risks ResMed faces?
ResMed's own risk factors are in Item 1A of its 10-K for fiscal 2026, filed Aug 13, 2026. Risks that are common among companies in the health care equipment industry include Regulation; pricing and reimbursement; competition; litigation; supply. The first: Approvals, safety rules and government oversight shape what it can sell and how. Source: 10-K, Item 1A Risk Factors.
Where do these ResMed numbers come from?
The 10-K filed Aug 13, 2026 (fiscal 2026) and the 10-Q filed Oct 30, 2026 (quarter ended Sep 30, 2026), as published in the SEC's XBRL data. Click any number to open the filing it came from. Methodology explains how fiscal years and missing numbers are handled.
Tracked funds that report owning ResMed
- Citadel Advisors: 508,284 shares, reported value $99.1M at Jun 30, 2026 (+53.0% in shares since the filing for Mar 31, 2026). Form 13F filed Sep 2, 2026.
- Two Sigma Investments: 411,036 shares, reported value $80.1M at Jun 30, 2026 (+31.5% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
- Millennium Management: 204,731 shares, reported value $39.9M at Jun 30, 2026 (+43.9% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
- Bridgewater Associates: 67,381 shares, reported value $13.1M at Jun 30, 2026 (+71.7% in shares since the filing for Mar 31, 2026). Form 13F filed Aug 14, 2026.
- Renaissance Technologies: 1,620 shares, reported value $0.3M at Jun 30, 2026 (new in this filing). Form 13F filed Aug 13, 2026.
From each fund’s latest Form 13F, which is filed up to 45 days after quarter end and lists long positions in US-listed stocks only. A listing here is a fact about a filing, not a view on the stock. What a 13F does and doesn’t show.
Disclosures
- Editor holdings in RMD
- The editor holds no position in ResMed (RMD). As of Nov 11, 2026.
- Trading rule
- The editor does not buy or sell RMD from 3 days before to 3 days after this page is published or substantively updated.
- Compensation
- Nobody paid for this page. No affiliate links on this page.
- Sources
- The company's SEC filings, linked next to each number or, for charts, in the source line under them.
- Last updated
- Nov 9, 2026
General education, the same for every reader. Not a recommendation to buy, sell or hold RMD, and it doesn't consider your situation.
Compare with peers
| Company | Fiscal year | Revenue | Revenue growth | Net income |
|---|---|---|---|---|
| ResMedRMD | FY2026 | $5.7B | +9.9% | $1.5B |
| AbbottABT | FY2025 | $44.3B | +5.7% | $6.5B |
| Intuitive SurgicalISRG | FY2025 | $10.1B | +20.5% | $2.9B |
| MedtronicMDT | FY2026 | $36.4B | +8.4% | $4.8B |
| StrykerSYK | FY2025 | $25.1B | +11.2% | $3.2B |
Each row is that company’s latest fiscal year from its own 10-K, using its own revenue and net income lines. Fiscal years end in different months, and line definitions differ (banks, insurers and oil companies count revenue differently), so this is a rough side-by-side, not a like-for-like comparison.
More company files
- BSX Boston Scientific
- BDX Becton Dickinson
- EW Edwards Lifesciences
- IDXX Idexx Laboratories
- GEHC GE HealthCare
- DXCM Dexcom
- WST West Pharmaceutical Services
- STE Steris
- ZBH Zimmer Biomet
- RVTY Revvity
- PODD Insulet
- BAX Baxter International
- ALGN Align Technology
- COO Cooper Companies
- AAPL Apple
- MSFT Microsoft
- NVDA Nvidia
- AMZN Amazon
- GOOGL Alphabet
- META
- BRK.B Berkshire Hathaway
- AVGO Broadcom
- JPM JPMorgan Chase
- LLY Eli Lilly
- MU Micron
- WMT Walmart
- AMD
- V Visa
- XOM ExxonMobil
- JNJ Johnson & Johnson
New to filings? Learn has plain-English explainers and Tools has calculators. Methodology & Disclosures covers where every number comes from.